Blood Test Potentially Predicts Alzheimer’s Disease
By LabMedica International staff writers Posted on 03 Jun 2014 |
Image: An Acquity H-class Ultra Performance Liquid Chromatography (UPLC) system (Photo courtesy of Waters).
A blood test has the potential to predict Alzheimer’s disease before patients start showing symptoms and it could be the key to curing this devastating illness.
Current biomarkers for Alzheimer’s disease (AD) are limited because they are time consuming, invasive or expensive and while blood-based biomarkers may be a more attractive option, none can currently detect preclinical AD with the required sensitivity and specificity.
Scientists at Georgetown University Medical Center (Washington DC, USA) enrolled cognitively healthy adults age 70 years and older, in a five year observational study. Over the course of the study, 74 participants met criteria for amnestic mild cognitive impairment (aMCI) or mild Alzheimer's disease (AD). Blood samples were taken from selected participants.
To measure the biomarkers the team used liquid chromatography–mass spectrometry methods using an Acquity H-class Ultra Performance Liquid Chromatography (UPLC) system and mass spectrometry was performed on a quadrupole time-of-flight (Q-TOF) instrument, the Xevo G2 QTOF (Waters Corporation, Milford, MA, USA). Targeted metabolomic analysis of plasma samples was performed using the Absolute-IDQ P180 kit (BIOCRATES; Innsbruck, Austria).
The investigators discovered and validated a set of ten lipids from peripheral blood that predicted phenoconversion to either amnestic mild cognitive impairment or Alzheimer's disease within a two to three year timeframe with over 90% accuracy. This biomarker panel, reflecting cell membrane integrity, may be sensitive to early neurodegeneration of preclinical Alzheimer's disease.
Janet B. Kreizman, BA, the CEO of the American Association for Clinical Chemistry (AACC), said, “This discovery is a potentially enormous breakthrough in the fight against Alzheimer's. If research aimed at a cure for Alzheimer's is to move forward, it is crucial that Alzheimer's clinical trials find a way to recruit patients who are still asymptomatic, since they are the ones most likely to respond to treatment.” The expanded study will be presented at the upcoming AACC Annual Meeting & Clinical Lab Expo, which will be held July 27–31, 2014 in Chicago (IL, USA).
Related Links:
Georgetown University Medical Center
Waters Corporation
BIOCRATES
Current biomarkers for Alzheimer’s disease (AD) are limited because they are time consuming, invasive or expensive and while blood-based biomarkers may be a more attractive option, none can currently detect preclinical AD with the required sensitivity and specificity.
Scientists at Georgetown University Medical Center (Washington DC, USA) enrolled cognitively healthy adults age 70 years and older, in a five year observational study. Over the course of the study, 74 participants met criteria for amnestic mild cognitive impairment (aMCI) or mild Alzheimer's disease (AD). Blood samples were taken from selected participants.
To measure the biomarkers the team used liquid chromatography–mass spectrometry methods using an Acquity H-class Ultra Performance Liquid Chromatography (UPLC) system and mass spectrometry was performed on a quadrupole time-of-flight (Q-TOF) instrument, the Xevo G2 QTOF (Waters Corporation, Milford, MA, USA). Targeted metabolomic analysis of plasma samples was performed using the Absolute-IDQ P180 kit (BIOCRATES; Innsbruck, Austria).
The investigators discovered and validated a set of ten lipids from peripheral blood that predicted phenoconversion to either amnestic mild cognitive impairment or Alzheimer's disease within a two to three year timeframe with over 90% accuracy. This biomarker panel, reflecting cell membrane integrity, may be sensitive to early neurodegeneration of preclinical Alzheimer's disease.
Janet B. Kreizman, BA, the CEO of the American Association for Clinical Chemistry (AACC), said, “This discovery is a potentially enormous breakthrough in the fight against Alzheimer's. If research aimed at a cure for Alzheimer's is to move forward, it is crucial that Alzheimer's clinical trials find a way to recruit patients who are still asymptomatic, since they are the ones most likely to respond to treatment.” The expanded study will be presented at the upcoming AACC Annual Meeting & Clinical Lab Expo, which will be held July 27–31, 2014 in Chicago (IL, USA).
Related Links:
Georgetown University Medical Center
Waters Corporation
BIOCRATES
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines